title: Alpha-2 adrenergic activity of bromocriptine and quinpirole in chicken pineal gland. Effects on melatonin synthesis and [3H]rauwolscine binding.
abstract: In the pineal gland and retina of chickens, serotonin N-acetyl-transferase (NAT) activity and melatonin content are modulated by different receptors, alpha-2 adrenergic receptors in pineal gland and D2-dopamine receptors in retina. The effect of two D2-dopamine receptor agonists, bromocriptine and quinpirole (LY 171555), on melatonin synthesis in these tissues was investigated. Systemic administrations of bromocriptine and quinpirole decreased nocturnal NAT activity and melatonin content of both pineal gland and retina. Bromocriptine was equipotent in the two tissues, whereas quinpirole was approximately 100-fold more potent in retina than in pineal gland. In pineal gland, the suppressive effects of bromocriptine and quinpirole on NAT activity were blocked by yohimbine, a selective alpha-2 adrenergic receptor antagonist, but not by spiperone, a D2-dopamine receptor antagonist. In contrast, bromocriptine- and quinpirole-induced decreases of the enzyme activity in retina were antagonized by spiperone, and not affected by yohimbine. The nocturnal increase of NAT activity of pineal glands in vitro was inhibited with an order of potency clonidine greater than bromocriptine greater than quinpirole. Additionally, bromocriptine and quinpirole displaced the specific binding of [3H]rauwolscine, an alpha-2 adrenergic receptor antagonist, to membranes from chicken pineal gland, with potencies comparable to those observed for inhibition of NAT activity in vitro. It is suggested that bromocriptine and quinpirole, in addition to their D2-dopaminergic activity, can stimulate alpha-2 adrenergic receptors in pineal gland of chicken.
authors.affiliation: Emory University School of Medicine, Department of Pharmacology, Atlanta, Georgia.
authors.forename: J
authors.initials: J
authors.lastname: Zawilska
authors.forename: P M
authors.initials: PM
authors.lastname: Iuvone
mesh_terms: D000818:Animals; D001191:Arylamine N-Acetyltransferase / Q000378:metabolism; D001665:Binding Sites; D001971:Bromocriptine / Q000494:pharmacology*; D002645:Chickens; D003000:Clonidine / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology*; D004873:Ergolines / Q000494:pharmacology*; D008297:Male; D008550:Melatonin / Q000096:biosynthesis; D008566:Membranes / Q000378:metabolism; D010870:Pineal Gland / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism / Q000648:ultrastructure; D019257:Quinpirole; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D012160:Retina / Q000201:enzymology / Q000378:metabolism / Q000648:ultrastructure; D014316:Tritium; D015016:Yohimbine / Q000378:metabolism
chemical_list: D015259:Dopamine Agents; D004873:Ergolines; D011942:Receptors, Adrenergic, alpha; D014316:Tritium; D019257:Quinpirole; D015016:Yohimbine; D001971:Bromocriptine; D001191:Arylamine N-Acetyltransferase; D008550:Melatonin; D003000:Clonidine